|Free Dividend Report|
|Stock Splits Calendar|
|MRNS Stock Split History|
|Preferred Stock Newsletter|
|MRNS Options Chain|
|Stock Message Boards|
Marinus Pharmaceuticals (MRNS) has 1 split in our MRNS split history database. The split for MRNS took place on September 23, 2020. This was a 1 for 4 reverse split, meaning for each 4 shares of MRNS owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 250 share position following the split.
When a company such as Marinus Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the MRNS split history from start to finish, an original position size of 1000 shares would have turned into 250 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Marinus Pharmaceuticals shares, starting with a $10,000 purchase of MRNS, presented on a split-history-adjusted basis factoring in the complete MRNS split history.
Growth of $10,000.00
Without Dividends Reinvested
|Average Annual Total Return:||-20.92%|
|About Marinus Pharmaceuticals|
|Marinus Pharmaceuticals is a pharmaceutical company focused on developing and commercializing products for patients suffering from rare genetic epilepsies and other seizure disorders. Co.'s product candidate, Ganaxolone, is a positive allosteric modulator of gamma-aminobutyric acid type A. Ganaxolone is being developed in formulations for two different routes of administration: intravenous and oral. Ganaxolone is a synthetic analog of allopregnanolone, an endogenous neurosteroid. The different formulations are intended to maximize therapeutic applications of ganaxolone for adult and pediatric patient populations, in acute and chronic care, and for in-patient and self-administered settings. According to our MRNS split history records, Marinus Pharmaceuticals has had 1 split.|
|MRNS Split History Table|
|09/23/2020||1 for 4|
|Healthcare Stock Splits|
|MRNS is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:
Also explore: MRNS shares outstanding history